Skip to content
Subscriber Only
Business
Prognosis

Japan Cuts Reliance on AstraZeneca Vaccine With More Pfizer Jabs

  • Set to agree on 50 million more Pfizer shots by Sept.: Nikkei
  • Addition could help protect most residents with mRNA jabs
A doctor administers a dose of the Pfizer-BioNTech vaccine at a nursing home in Kawasaki, on April 12.
A doctor administers a dose of the Pfizer-BioNTech vaccine at a nursing home in Kawasaki, on April 12.Photographer: Noriko Hayashi/Bloomberg

Japan is poised to buy more doses of the Covid-19 vaccine developed by Pfizer Inc. and BioNTech SE, a move that would pave the way for the country to immunize its adult population without using any of the controversial shots it purchased from AstraZeneca Plc.

Pfizer is expected to provide an additional 50 million doses by September in a contract that could be agreed on this month, the Nikkei said Wednesday, without citing sources. The purchase would bring Japan’s total supply of the companies’ vaccine to 195 million doses. The nation also has an agreement for 50 million doses of Moderna Inc.’s shot, creating enough supply of the two-dose immunizations to protect around 110 million residents above the age of 16.